Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joohyuk Sohn

Showing results (51-60 of 130) with videos related to

Pageof 13
Sort By:
Plos One|April 8, 2016
The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast CancerYoung Kwang Chae, Debora de Melo Gagliato, Sachin Gopalkrishna Pai, et al.
Cancer Research and Treatment|April 30, 2025
Safety and Effectiveness of Eribulin in Patients with Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes in Real-World Clinical Practice: A 6-Year Post-Marketing Surveillance Study in South KoreaYee Soo Chae, Kyung A Kwon, Moon Hee Lee, et al.
Cancer Research and Treatment|August 18, 2017
Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer PatientsSeho Park, Ja Seung Koo, Gun Min Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|January 3, 2021
Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO studyJae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, et al.
Nature Communications|March 13, 2026
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancerAnn E Collier, Stephanie Hilz, Alejandro M Chibly, et al.
International Journal of Cancer|February 6, 2019
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patientsJi-Yeon Kim, Eunjin Lee, Kyunghee Park, et al.
International Journal of Molecular Sciences|August 26, 2022
Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating TranscriptsSunyoung Park, Sungwoo Ahn, Jee Ye Kim, et al.
JCI Insight|April 21, 2026
Long-acting IL-7 induces distinct transcriptomic features in peripheral T cells of patients with solid tumorsHo Cheol Jang, Jeong Yeon Kim, Sojeong Kim, et al.
Oncotarget|February 9, 2018
CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticatorYong Wha Moon, Hee-Jung An, Ja Seung Koo, et al.
International Journal of Cancer|April 27, 2021
Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancerHyehyun Jeong, Jae Ho Jeong, Jeong Eun Kim, et al.
Pageof 13

Showing results (51-60 of 130) with videos related to

Sort By:
Pageof 13
Plos One|April 8, 2016
The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast CancerYoung Kwang Chae, Debora de Melo Gagliato, Sachin Gopalkrishna Pai, et al.
Cancer Research and Treatment|April 30, 2025
Safety and Effectiveness of Eribulin in Patients with Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes in Real-World Clinical Practice: A 6-Year Post-Marketing Surveillance Study in South KoreaYee Soo Chae, Kyung A Kwon, Moon Hee Lee, et al.
Cancer Research and Treatment|August 18, 2017
Feasibility of Charcoal Tattooing of Cytology-Proven Metastatic Axillary Lymph Node at Diagnosis and Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer PatientsSeho Park, Ja Seung Koo, Gun Min Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|January 3, 2021
Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO studyJae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, et al.
Nature Communications|March 13, 2026
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancerAnn E Collier, Stephanie Hilz, Alejandro M Chibly, et al.
International Journal of Cancer|February 6, 2019
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patientsJi-Yeon Kim, Eunjin Lee, Kyunghee Park, et al.
International Journal of Molecular Sciences|August 26, 2022
Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating TranscriptsSunyoung Park, Sungwoo Ahn, Jee Ye Kim, et al.
JCI Insight|April 21, 2026
Long-acting IL-7 induces distinct transcriptomic features in peripheral T cells of patients with solid tumorsHo Cheol Jang, Jeong Yeon Kim, Sojeong Kim, et al.
Oncotarget|February 9, 2018
CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticatorYong Wha Moon, Hee-Jung An, Ja Seung Koo, et al.
International Journal of Cancer|April 27, 2021
Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancerHyehyun Jeong, Jae Ho Jeong, Jeong Eun Kim, et al.
Pageof 13